Daiichi Move Aids Global Competition With U.S., Israel
This article was originally published in PharmAsia News
Executive Summary
The move by Japan's Daiichi Sankyo to buy India's largest pharmaceutical firm, Ranbaxy Laboratories, is seen as aiding the Japanese firm's efforts to compete with U.S. and Israeli rivals in the global drug market. By merging with Ranbaxy, Daiichi becomes the world's 15th largest drug maker, giving it access to Ranbaxy's generics empire, particularly in the United States where Daiichi has not been much of a player. By buying Ranbaxy, Daiichi is positioning itself in the U.S. market to be a major supplier in a generics market that comprises nearly half of U.S. prescriptions. (Click here for more